You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

MOVIPREP Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Moviprep patents expire, and what generic alternatives are available?

Moviprep is a drug marketed by Salix Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in twenty-two countries.

The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Moviprep

Annual sales in 2021 were $646k (peak sales were $33mm in 2009).

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MOVIPREP?
  • What are the global sales for MOVIPREP?
  • What is Average Wholesale Price for MOVIPREP?
Drug patent expirations by year for MOVIPREP
Drug Prices for MOVIPREP

See drug prices for MOVIPREP

Drug Sales Revenue Trends for MOVIPREP

See drug sales revenues for MOVIPREP

Recent Clinical Trials for MOVIPREP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
North Denmark Regional HospitalPhase 4
Aalborg University HospitalPhase 4
Radboud University Medical CenterN/A

See all MOVIPREP clinical trials

Paragraph IV (Patent) Challenges for MOVIPREP
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MOVIPREP For Oral Solution ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch 021881 1 2007-11-27

US Patents and Regulatory Information for MOVIPREP

MOVIPREP is protected by two US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MOVIPREP

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 7,169,381 ⤷  Subscribe
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 7,658,914 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MOVIPREP

See the table below for patents covering MOVIPREP around the world.

Country Patent Number Title Estimated Expiration
Slovenia 1567193 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2004037292 ⤷  Subscribe
China 1705494 Colon cleansing compositions and methods ⤷  Subscribe
Australia 2008100865 Colon cleansing compositions ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MOVIPREP

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3141251 132021000000044 Italy ⤷  Subscribe PRODUCT NAME: UN PRODOTTO MEDICINALE COSTITUITO DA UNA COMBINAZIONE DI UNA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E UNA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA, LA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, SOLFATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO E LA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, ACIDO ASCORBICO, ASCORBATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO.(PLENVU); AUTHORISATION NUMBER(S) AND DATE(S): IS/1/17/083/01, 20171016;045671017, 045671029, 045671031, 045671043, 045671056, 20171213
3141251 C202130017 Spain ⤷  Subscribe PRODUCT NAME: COMBINACION DE PRINCIPIOS ACTIVOS EN DOS DOSIS, EN LA QUE LA PRIMERA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, SULFATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO, Y LA SEGUNDA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, ACIDO ASCORBICO, ASCORBATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO.; NATIONAL AUTHORISATION NUMBER: 82959-SE/H/1801/001/DC; DATE OF AUTHORISATION: 20180525; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): IS/1/17/083/01; DATE OF FIRST AUTHORISATION IN EEA: 20171016
3141251 301099 Netherlands ⤷  Subscribe PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

MOVIPREP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Moviprep

Introduction to Moviprep

Moviprep is a bowel preparation drug used to cleanse the colon before procedures such as colonoscopy. It is a polyethylene glycol (PEG)-based solution, known for its effectiveness and relatively fewer side effects compared to other types of bowel preparation drugs.

Market Drivers

Increasing Incidence of Colorectal Diseases

The global market for colonoscopy bowel preparation drugs, including Moviprep, is driven by the rising incidence of colorectal diseases. Colorectal cancer is one of the most common cancers worldwide, and regular colonoscopy screenings are essential for early detection and prevention. According to the World Health Organization, there were over 1.9 million new cases of colorectal cancer and more than 930,000 deaths from the disease in 2020, with projections indicating a significant increase by 2040[4].

Preference for Effective and Less Invasive Methods

There is a growing preference for effective and less invasive bowel preparation methods. Patients and healthcare providers are increasingly opting for PEG-based solutions like Moviprep due to their efficacy and lower side effect profile compared to other types of bowel preparation drugs[3][4].

Technological Advancements

Technological advancements in drug development are also driving the market. Innovations in formulation and delivery methods, such as the development of tablet forms like Sutab, are enhancing patient compliance and comfort, thereby boosting the demand for bowel preparation drugs[4].

Market Trends

Growing Focus on Patient-Friendly Drugs

There is a growing focus on developing patient-friendly bowel preparation drugs. Manufacturers are working to improve the taste, ease of use, and overall patient experience, which is expected to increase the adoption of these drugs[3][4].

Increasing Adoption of Home-Based Preparation Methods

Home-based bowel preparation methods are becoming more popular, reducing the need for hospital visits and making the process more convenient for patients. This trend is expected to continue, driving the demand for drugs like Moviprep[3].

Financial Performance of Moviprep

Revenue Trends

Moviprep has shown consistent revenue performance over the years. For instance, in the third quarter of 2020, Moviprep generated $29 million in revenue, down from $55 million in 2020, but still indicating a stable market presence[2][5].

Market Share and Competition

Moviprep competes in a market dominated by PEG-based drugs. Major players in the market include Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, and Salix Pharmaceuticals. These companies are focusing on product innovation, strategic collaborations, and expanding their geographical presence to strengthen their market position[3].

Regional Performance

The market for colonoscopy bowel preparation drugs, including Moviprep, is strongest in North America and Europe due to the high prevalence of colorectal diseases and robust healthcare infrastructure. These regions have favorable reimbursement policies for colonoscopy procedures, which encourages individuals to undergo screenings and boosts the demand for bowel preparation drugs[3][4].

Challenges and Restraints

High Costs and Side Effects

Despite its effectiveness, Moviprep faces challenges such as high costs and potential side effects. The drug can cause metabolic acidosis, particularly high anion gap metabolic acidosis, due to its sulfate content. These side effects can impact patient compliance and overall market growth[1].

Cross-Study Comparisons and Safety Concerns

Studies have shown varying rates of high anion gap and low serum bicarbonate levels in patients using Moviprep compared to other bowel preparation drugs. These differences highlight the need for careful monitoring and management of potential side effects[1].

Future Outlook

Market Growth Projections

The global colonoscopy bowel preparation drugs market, which includes Moviprep, is expected to exhibit a Compound Annual Growth Rate (CAGR) of 4.9% from 2023 to 2030. The market is projected to grow from US$ 2000.5 million in 2023 to US$ 2796.1 million by 2030[4].

Expansion in Emerging Economies

There are significant growth opportunities in emerging economies, where the demand for effective and less invasive bowel preparation methods is increasing. Expanding into these markets could further boost the revenue and market share of Moviprep[3][4].

Key Takeaways

  • Moviprep is a PEG-based bowel preparation drug with a high success rate in colon cleansing.
  • The market is driven by the increasing incidence of colorectal diseases and the preference for effective and less invasive methods.
  • Technological advancements and patient-friendly formulations are key trends.
  • Despite high costs and potential side effects, Moviprep remains a significant player in the market.
  • The global market is expected to grow at a CAGR of 4.9% from 2023 to 2030.

FAQs

1. What is Moviprep used for?

Moviprep is used to cleanse the colon before procedures such as colonoscopy.

2. What are the key drivers of the Moviprep market?

The key drivers include the increasing incidence of colorectal diseases, preference for effective and less invasive methods, and technological advancements in drug development.

3. What are the potential side effects of Moviprep?

Moviprep can cause high anion gap metabolic acidosis and low serum bicarbonate levels due to its sulfate content.

4. How does Moviprep compare to other bowel preparation drugs?

Moviprep has a high success rate in colon cleansing and is preferred for its efficacy and fewer side effects compared to other types of bowel preparation drugs.

5. What is the projected market growth for Moviprep and similar drugs?

The global colonoscopy bowel preparation drugs market is expected to exhibit a CAGR of 4.9% from 2023 to 2030, reaching US$ 2796.1 million by 2030.

Cited Sources:

  1. FDA NDA Summary: "203595Orig1s000 - accessdata.fda.gov"
  2. Bausch Health Financial Results: "4Q & FY 2021 - Financial Results - Bausch Health Companies Inc."
  3. Colonoscopy Bowel Preparation Drugs Market Analysis: "Colonoscopy Bowel Preparation Drugs Market Size, Forecast"
  4. Global Colonoscopy Bowel Preparation Drugs Market: "Global Colonoscopy Bowel Preparation Drugs Market Size, Forecast"
  5. Bausch Health Earnings Presentation: "Financial Results - Bausch Health"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.